5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 9,525,931 | $388,467,484 | -4% | 2.57% |
| 2. | Citadel Investment Group Ken Griffin | 1,604,628 | $65,436,730 | +38% | 0.01% |
| 3. | Rokos Capital Management Chris Rokos | 1,389,296 | $56,474,882 | 0.54% | |
| 4. | Casdin Capital Eli Casdin | 1,275,000 | $51,994,500 | 4.54% | |
| 5. | Himension Capital Jay Chen | 1,145,091 | $46,696,811 | 4.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.50 | 4,250 | Officer | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | Officer | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | Director | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | Director | 2,603,646 | 2016-05-11 | Filing | |
| $18.00 | 300,000 | Large Shareholder | 790,527 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.33 | 265 | Director | 12,261 | 2023-07-31 | Filing | |
| $39.30 | 1,867 | Director | 12,526 | 2023-07-06 | Filing | |
| $40.51 | 360 | Officer | 45,146 | 2023-07-03 | Filing | |
| $45.00 | 5,000 | Officer | 45,146 | 2023-06-20 | Filing | |
| $43.88 | 1,088 | Officer | 55,279 | 2023-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,185,151 | $333,790,457 | 0% | |
| 2. | 8,054,963 | $328,481,402 | 0% | |
| 3. | 3,492,791 | $142,436,017 | 0% | |
| 4. | 3,394,656 | $138,434,072 | 0.1% | |
| 5. | 3,394,656 | $138,298,285 | 1.45% |
News See All
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Intellia Therapeutics' Second Quarter 2023 Earnings Conference Call. My name is Drew and I will be your conference operator today.
10 DNA Stocks Billionaires Are Loading Up On
Genomics is the study of a complete set of DNA within an organism.
13 Best Future Stocks for the Long-Term
Investing these days is a ride not for the faint hearted.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Intellia Therapeutics' First Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
5 Gene Editing Stocks With the Best Long-Term Potential
In this article, we will take a look at the 5 gene editing stocks with the best long-term potential.
Top 5 CRISPR Stocks To Buy
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) and its affiliated companies specialize in creating a platform for cell programming.
5 Most Promising Gene Editing Stocks According to Analysts
In this article, we will take a look at the 5 most promising gene editing stocks according to analysts.
12 Cheap Healthcare Stocks to Buy in 2023
The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades.
Billionaire Hedge Funds
